India's patent power casts new shadow over drug pricing
By Freny Patel ( October 15, 2026, 20:18 GMT | Comment) -- Pharmaceutical companies in India could face greater pressure to cut prices, expand patient-assistance programs or negotiate voluntary licenses after a court clarified that the government can authorize the use of patented medicines when their cost makes treatment unaffordable.Pharmaceutical companies in India could face greater pressure to cut prices, expand patient-assistance programs or negotiate voluntary licenses after a court clarified that the government can authorize the use of patented medicines when their cost makes treatment unaffordable....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.